respiratory
Cystic fibrosis

Fourth time lucky for CF drug’s PBS listing bid


After being knocked back three times for PBS listing, the cystic fibrosis treatment lumacaftor with ivacaftor (Orkambi) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee At its July meeting the PBAC made  a recommendation for a Section 100 (Highly Specialised Drugs Program) Authority Required listing for the drug as treatment of cystic ...

Already a member?

Enter your email to keep reading.


OR